Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery, development and commercialization of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases.
Our primary focus is on developing novel, small molecule Selective Inhibitor of Nuclear Export, or SINE, compounds that inhibit the nuclear export protein XPO1. Our lead oral SINE compound selinexor is being evaluated in multiple late stage clinical trials in patients with hematologic and solid tumor malignancies. We are seeking our first regulatory approval for selinexor in relapsed or refractory multiple myeloma.
In addition to selinexor, we are also advancing a pipeline of novel, oral drug candidates, including eltanexor as a treatment for myelodysplastic syndrome, colorectal cancer and castrate-resistant prostate cancer, verdinexor as an anti-viral agent, as well as a potential treatment for cancer in companion animals, and KPT-9274, a dual PAK4/NAMPT inhibitor for the treatment of patients with advanced solid malignancies or non-Hodgkin’s lymphoma.
Karyopharm was founded by Dr. Sharon Shacham and is headquartered in Newton, MA.
